A more bioavailable BET-PROTAC ARV-771, which recruits VHL E3 ligase, was also more potent in the murine xenograft model of secondary AML, compared with BET inhibitors, in terms of the reduction of tumor growth and overall survival, without significant impact on the animals’ weight [102]. The gene discussed is DNER; the disease is acute myeloid leukemia.